Literature DB >> 17967857

Oral vaccination with Salmonella enterica as a cruzipain-DNA delivery system confers protective immunity against Trypanosoma cruzi.

Silvia I Cazorla1, Pablo D Becker, Fernanda M Frank, Thomas Ebensen, María J Sartori, Ricardo S Corral, Emilio L Malchiodi, Carlos A Guzmán.   

Abstract

To stimulate both local and systemic immune responses against Trypanosoma cruzi, Salmonella enterica serovar Typhimurium aroA was exploited as a DNA delivery system for cruzipain (SCz). In a murine model we compared SCz alone (GI) or coadministered with Salmonella carrying a plasmid encoding granulocyte-macrophage colony-stimulating factor (GII), as well as protocols in which SCz priming was followed by boosting with recombinant cruzipain (rCz) admixed with either CpG-ODN (GIII) or MALP-2, a synthetic derivative of a macrophage-activating lipopeptide of 2 kDa from Mycoplasma fermentans (GIV). The results showed that protocols that included four oral doses of SCz (GI) elicited mainly a mucosal response characterized by immunoglobulin A (IgA) secretion and proliferation of gut-associated lymphoid tissue cells, with weak systemic responses. In contrast, the protocol that included a boost with rCz plus CpG (GIII) triggered stronger systemic responses in terms of Cz-specific serum IgG titers, splenocyte proliferation, gamma interferon (IFN-gamma) secretion, and delayed-type hypersensitivity response. Trypomastigote challenge of vaccinated mice resulted in significantly lower levels of parasitemia compared to controls. Protection was abolished by depletion of either CD4+ or CD8+ T cells. Parasite control was also evident from the reduction of tissue damage, as revealed by histopathologic studies and serum levels of enzymes that are markers of muscle injury in chronic Chagas' disease (i.e., creatine kinase, aspartate aminotransferase, and lactate dehydrogenase). Enhanced release of IFN-gamma and interleukin-2 was observed in GI and GII upon restimulation of splenocytes in the nonparasitic phase of infection. Our results indicate that Salmonella-mediated delivery of Cz-DNA by itself promotes the elicitation of an immune response that controls T. cruzi infection, thereby reducing parasite loads and subsequent damage to muscle tissues.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17967857      PMCID: PMC2223668          DOI: 10.1128/IAI.01163-07

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  53 in total

1.  Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants.

Authors:  M Roman; E Martin-Orozco; J S Goodman; M D Nguyen; Y Sato; A Ronaghy; R S Kornbluth; D D Richman; D A Carson; E Raz
Journal:  Nat Med       Date:  1997-08       Impact factor: 53.440

Review 2.  Salmonella-based vaccines for infectious diseases.

Authors:  Young Min Kwon; Mandy M Cox; Leona N Calhoun
Journal:  Expert Rev Vaccines       Date:  2007-04       Impact factor: 5.217

3.  Different Trypanosoma cruzi strains promote neuromyopathic damage mediated by distinct T lymphocyte subsets.

Authors:  G A Mirkin; A M Celentano; E L Malchiodi; M Jones; S M González Cappa
Journal:  Clin Exp Immunol       Date:  1997-02       Impact factor: 4.330

4.  Oral somatic transgene vaccination using attenuated S. typhimurium.

Authors:  A Darji; C A Guzmán; B Gerstel; P Wachholz; K N Timmis; J Wehland; T Chakraborty; S Weiss
Journal:  Cell       Date:  1997-12-12       Impact factor: 41.582

Review 5.  Detection of Trypanosoma cruzi with the polymerase chain reaction and in situ hybridization in infected murine cardiac tissue.

Authors:  J E Lane; D Olivares-Villagomez; C L Vnencak-Jones; T L McCurley; C E Carter
Journal:  Am J Trop Med Hyg       Date:  1997-06       Impact factor: 2.345

6.  Amastigote surface proteins of Trypanosoma cruzi are targets for CD8+ CTL.

Authors:  H P Low; M A Santos; B Wizel; R L Tarleton
Journal:  J Immunol       Date:  1998-02-15       Impact factor: 5.422

7.  "Autoimmune rejection" of neonatal heart transplants in experimental Chagas disease is a parasite-specific response to infected host tissue.

Authors:  R L Tarleton; L Zhang; M O Downs
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

8.  Detection of parasite DNA in Chagas' heart disease.

Authors:  S Brandariz; A Schijman; C Vigliano; P Arteman; R Viotti; C Beldjord; M J Levin
Journal:  Lancet       Date:  1995-11-18       Impact factor: 79.321

9.  Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans acting at picomolar concentration.

Authors:  P F Mühlradt; M Kiess; H Meyer; R Süssmuth; G Jung
Journal:  J Exp Med       Date:  1997-06-02       Impact factor: 14.307

10.  CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity.

Authors:  R S Chu; O S Targoni; A M Krieg; P V Lehmann; C V Harding
Journal:  J Exp Med       Date:  1997-11-17       Impact factor: 14.307

View more
  29 in total

1.  Coadministration of cruzipain and GM-CSF DNAs, a new immunotherapeutic vaccine against Trypanosoma cruzi infection.

Authors:  Natacha Cerny; Andrés Sánchez Alberti; Augusto E Bivona; Mauricio C De Marzi; Fernanda M Frank; Silvia I Cazorla; Emilio L Malchiodi
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

Review 2.  Host-parasite interactions in trypanosomiasis: on the way to an antidisease strategy.

Authors:  Nicolas Antoine-Moussiaux; Philippe Büscher; Daniel Desmecht
Journal:  Infect Immun       Date:  2009-01-21       Impact factor: 3.441

3.  Tc52 amino-terminal-domain DNA carried by attenuated Salmonella enterica serovar Typhimurium induces protection against a Trypanosoma cruzi lethal challenge.

Authors:  Marina N Matos; Silvia I Cazorla; Augusto E Bivona; Celina Morales; Carlos A Guzmán; Emilio L Malchiodi
Journal:  Infect Immun       Date:  2014-07-28       Impact factor: 3.441

4.  A TLR2 agonist is a more effective adjuvant for a Chlamydia major outer membrane protein vaccine than ligands to other TLR and NOD receptors.

Authors:  Chunmei Cheng; Pooja Jain; Ilham Bettahi; Sukumar Pal; Delia Tifrea; Luis M de la Maza
Journal:  Vaccine       Date:  2011-07-08       Impact factor: 3.641

Review 5.  Modulation of immune response in experimental Chagas disease.

Authors:  Beatriz Basso
Journal:  World J Exp Med       Date:  2013-02-20

6.  Prophylactic efficacy of TcVac2 against Trypanosoma cruzi in mice.

Authors:  Shivali Gupta; Nisha Jain Garg
Journal:  PLoS Negl Trop Dis       Date:  2010-08-10

Review 7.  Enhancing oral vaccine potency by targeting intestinal M cells.

Authors:  Ali Azizi; Ashok Kumar; Francisco Diaz-Mitoma; Jiri Mestecky
Journal:  PLoS Pathog       Date:  2010-11-11       Impact factor: 6.823

8.  Delivery of antigenic candidates by a DNA/MVA heterologous approach elicits effector CD8(+)T cell mediated immunity against Trypanosoma cruzi.

Authors:  Shivali Gupta; Nisha Jain Garg
Journal:  Vaccine       Date:  2012-10-15       Impact factor: 3.641

Review 9.  Differential regional immune response in Chagas disease.

Authors:  Juliana de Meis; Alexandre Morrot; Désio Aurélio Farias-de-Oliveira; Déa Maria Serra Villa-Verde; Wilson Savino
Journal:  PLoS Negl Trop Dis       Date:  2009-07-07

10.  Inhibition of HIV-1 replication in human monocyte-derived macrophages by parasite Trypanosoma cruzi.

Authors:  Guadalupe Andreani; Ana M Celentano; María E Solana; Silvia I Cazorla; Emilio L Malchiodi; Liliana A Martínez Peralta; Guillermina L Dolcini
Journal:  PLoS One       Date:  2009-12-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.